Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)

• Status: Recruiting
• Trial end date: 2023-05-30
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate the effect of dapagliflozin on liver function of patient with NAFLD and T2DM.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rehab Werida
• Collaborator: University of Alexandria
• Treatments: Dapagliflozin

Criteria

Inclusion Criteria:

1. Type 2 diabetes mellitus patients.

2. HbA1C < 8.5.

3. Patients were They were having fatty liver changes on abdominal ultrasound and mild to moderate elevation of serum liver enzymes.

4. BMI more than 30

Exclusion Criteria:

1. Patients with a history of alcohol, smoking, uncontrolled diabetes.

2. (HbA1c > 9.0).

3. Pregnancy.

4. Lactation.

5. Hemochromatosis.

6. Thyroid disorders.

7. Renal dysfunction.

8. Cardiac problem.

9. Chronic liver and decompensated liver disease in the form of hepatitis B and C.